Reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’: reply from the authors

Abstract

We thank Yélamos et al. for their interest in our nicotinamide chemoprevention studies.¹ Some of their comments are pertinent, while others are based on a flawed interpretation of our data.

Zhao² previously commented on (nonsignificant) numerical differences in the frequency of adverse-event term groupings (mucocutaneous infections) between the placebo and nicotinamide groups in our ONTRAC chemoprevention study (Oral Nicotinamide To Reduce Actinic Cancer).³ As stated previously, chance remains a highly plausible explanation for the numerically higher mucocutaneous infections in the nicotinamide arm and also, for example, for the numerically lower respiratory infections observed in the nicotinamide arm.⁴

This article is protected by copyright. All rights reserved.

http://ift.tt/2gC6X8i